People on the Move
Achaogen
Achaogen, a biopharma company developing antibacterials against multi-drug resistant (MDR) gram-negative infections, has appointed Alan Colowick and Kent Lieginger to its Board of Directors.
Scott Rocklage and Camille Samuels will step down as directors on March 20, 2015.
Colowick has held senior positions at Celgene, Gloucester Pharmaceuticals, Geron Corporation., and Amgen.
Lieginger, most recently served as Senior VP at Genentech and as Director of the Genentech Foundation since 2005. He has also been Vice President, National Insurer and Employer Segment (Managed Markets Division) at GSK.
Achaogen’s lead product candidate is plazomicin for bacterial infections due to MDR Enterobacteriaceae, including CRE. The programme is part-funded by BARDA, the Biomedical Advanced Research and Development Authority.